Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV VAX
- Development stage
- Preclinical
- Lead developer
- Akagera Medicines Africa
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Akagera Medicines Africa is developing a multivalent mRNA-based vaccine for the prevention or treatment of HIV. This candidate utilizes a ligand-directed lipid nanoparticle (LNP) delivery system specifically engineered to target dendritic cells and other antigen-presenting cells (APCs). By delivering mRNA directly to these key immune cells, the vaccine aims to elicit potent T-cell responses and the production of neutralizing antibodies. The program includes two distinct tracks: HIV VAX (LMIC), intended for low- and middle-income countries, and HIV VAX (HIC), intended for high-income countries. The vaccine is currently in the preclinical stage of development.
- Other names
- HIV vaccine (Akagera Medicines)ligand-directed multivalent mRNA-LNP HIV vaccine
Beyond the preview
Go deeper on HIV VAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV VAX.